About Cidara Therapeutics
Cidara Therapeutics is a publicly listed company based in San Diego (United States) founded in 2013, and was acquired by Merck in November 2025. Novel anti-infectives for bacterial and fungal infections are developed. Cidara Therapeutics has raised $78.35 million across 8 funding rounds from investors including Merck, Fidelity Investments and NIH. The company has 38 employees. Its chief executive, as recorded, is Jeffrey Stein. Its website cidara.com draws about 16 thousand monthly visits. Cidara Therapeutics offers products and services including Cloudbreak Platform. Its focus areas include Life Sciences, Immunotherapy, Diversified and Infectious Diseases. Its legal entity is CIDARA THERAPEUTICS, INC. Its competitors include BeiGene, Vir Biotechnology and Vaxcyte; 3 of its 3 listed competitors have raised funding.
Company details
Developer of novel anti-infectives for infectious diseases (bacterial and fungal). Its first product candidate is CD101 IV, an intravenous therapy in phase 1 trials for fungal infections. Besides, it has CD101 topical in the IND-enabling stage for the treatment of acute and recurrent vulvovaginal candidiasis (VVS). It has also developed a proprietary immunotherapy technology platform, Cloudbreak to develop drugs that direct immune cells to eliminate pathogens that cause infectious diseases. Its first Cloudbreak development candidate C001 is for the treatment of invasive aspergillosis.
- Annual Revenue$1.27 M (USD)-94.52as on Dec 31, 2024
- Net Profit-$168.03 M (USD)-632.75as on Dec 31, 2024
- EBITDA-$90.99 M (USD)-237.71as on Dec 31, 2024
- Total Equity Funding$78.35M (USD)
in 8 rounds
- Latest Funding Round$105M (USD), Post-IPO
Nov 2024
- InvestorsMerck
& 23 more
- Employee Count38
- Acquired byMerck
(Nov 2025)
Products & Services of Cidara Therapeutics
Cidara Therapeutics offers a comprehensive portfolio of products and services, including Cloudbreak Platform.
Platform creates drug-Fc conjugates for targeted disease treatment.
Apps and channels of Cidara Therapeutics
its YouTube channel Cidara Therapeutics has 46 subscribers and 2 videos.
Videos from Cidara Therapeutics
The most watched videos on Cidara Therapeutics's YouTube channel, Cidara Therapeutics (46 subscribers). Click a video to play it here.
More on Cidara Therapeutics.
Funding Insights of Cidara Therapeutics
Cidara Therapeutics has successfully raised a total of $78.35M across 8 strategic funding rounds. The most recent funding activity was a Post-IPO round of $105 million completed in November 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $78.35M
- Total Rounds 8
- Last Round Post-IPO — $105M
- First Round $36.33M
(Jun 2014)
- Investors Count 23
All 8 funding rounds of Cidara Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2024 | $105M | Post-IPO | – | – | |
| Apr 2024 | $240M | Post-IPO | – | – | – |
| Sep 2019 | $9.01M | Post-IPO | – | – | – |
| May 2018 | $1.56M | Post-IPO | – | – | – |
| May 2018 | $5.5M | Grant | – | – | |
| Oct 2017 | $20.16M | Post-IPO | – | – | |
| Feb 2015 | $42.02M | Series B | – | CAM Capital, Fidelity Investments | – |
| Jun 2014 | $36.33M | Series A | – | 5AM Ventures |
24 investors in total: 24 institutional.
Investors in Cidara Therapeutics
Cidara Therapeutics has secured backing from 24 investors, including venture fund and institutional investors. Prominent investors backing the company include Merck, Fidelity Investments and NIH.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm focused on tech sectors | venrock.com | Palo Alto, United States | ||
| tcgcrossover.com | ||||
US private equity investments are managed by BVF Partners. | bvflp.com | San Francisco, United States | ||
Venture capital and private equity firm | vivocapital.com | Palo Alto, United States | ||
Private equity firm focused on company buyouts | gppfunds.com | Greenwich, United States | ||
PE firm investing in Asia and Europe | 1993 | bbbiotech.ch | Schaffhausen, Switzerland | |
Investment opportunities in healthcare are managed by Broadfin Capital. | 2005 | broadfin.com | Melville, United States | |
Health-tech companies are targeted for venture capital investments. | 1999 | perceptivelife.com | New York, United States | |
Venture capital fund backed incubator focused on the healthcare startups | 5amventures.com | San Francisco, United States | ||
Healthcare sector private equity investments are managed by the firm. | 1991 | frazierhealthcare.com | Seattle, United States |
Investor details for Cidara Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Cidara Therapeutics
34 people are tracked at Cidara Therapeutics (14 in leadership, 9 in board & advisors, 11 in team); the tracked headcount is 38.
| Name | Role | Group |
|---|---|---|
Jeffrey Stein | CEO | Leadership |
Shane Ward | COO & Chief Legal Officer | Leadership |
Donal Gallagher | Associate Director, Clinical Data Management | Leadership |
Laurel Conly | Associate Director, Clinical Project Management And Outsourcing | Leadership |
Les Tari | Chief Scientific Officer | Leadership |
Monica C. Sanford | Associate Director, Clinical Operations | Leadership |
Allen borchardt | Senior Director of Chemistry | Leadership |
Wesley Heaton | Vice President Technical Operations | Leadership |
Jodi Schinski | Senior Director, Regulatory Affairs | Leadership |
Rob Hughes | Senior Director, Pharmaceutical Sciences | Leadership |
Jennifer Duzak | Director, Purchasing, Facilities & Programs | Leadership |
Karen Mena | Director Clinical Operations | Leadership |
Jim Beitel | Chief Business Officer | Leadership |
Joaquin Sosa | Senior Director, Clinical Systems & Trial Management | Leadership |
Kieren Marr | Scientific Advisor | Board & advisors |
Frederick G. Hayden | Scientific Advisor | Board & advisors |
Johan A. Maertens | Scientific Advisor | Board & advisors |
Michael G. Ison | Scientific Advisor | Board & advisors |
Ted Schroeder | Director | Board & advisors |
Dan Burgess | Chairman | Board & advisors |
14 more people are available in the full profile.
Complete people profiles for Cidara Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Cidara Therapeutics
Cidara Therapeutics is a publicly listed company on the NASDAQ with ticker symbol CDTX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date15 Apr 2015
- Listed onNASDAQ: CDTX
- Listed entityCidara Therapeutics, Inc.
- Exchange sectorHealth technology
- ISINUS1717572069
- Share price$221.38 (+0.03% on the day) · 2026-01-08
- Market capitalisation$6.96B
- EPS (diluted, trailing year)$-11.78
- Volume (last session)2,691,011
- Analyst consensusNeutral
Financials of Cidara Therapeutics
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2024 | $1.3M | -$168.0M | -$91.0M |
| 2023 | $23.3M | -$22.9M | -$26.9M |
| 2022 | $64.5M | -$33.6M | -$33.4M |
| 2021 | $49.6M | -$42.5M | -$42.1M |
| 2020 | $12.1M | -$74.9M | -$71.6M |
Detailed financial statements for Cidara Therapeutics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Cidara Therapeutics
5 dated milestones of Cidara Therapeutics across 12 years, from founding to its latest funding, stage changes and deals.
- Founded Cidara Therapeutics is founded.
- Funding First funding round of $36.3M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $105.0M.
- Exit Acquired by Merck.
Competitors of Cidara Therapeutics
Cidara Therapeutics has 3 listed competitors in our database, 3 of them funded. They include BeiGene, Vir Biotechnology and Vaxcyte.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| vir.bio | 2017 | San Francisco, United States | $216M | 417 | Developer of therapeutics for the treatment of infectious diseases | |
| vaxcyte.com | 2013 | Foster, United States | $347M | 254 | Vaccines for infectious diseases are developed using cell-free protein synthesis. |
Detailed competitors of Cidara Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Cidara Therapeutics
The website of Cidara Therapeutics (cidara.com) receives about 16.3K visits a month and ranks #1,199,553 among all websites worldwide, #1,507 in Biotechnology and Pharmaceuticals.
- Monthly visits16.3K
▼ 27.5% vs previous month
- Unique visitors9.6K
per month
- Global rank#1,199,553
among all websites
- Category rank#1,507
Health · Biotechnology and Pharmaceuticals
- Bounce rate40%
- Pages per visit2.0
- Average visit52 sec
- DevicesDesktop 34% · Mobile 66%
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Cidara Therapeutics (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Cidara Therapeutics
Complete news archive for Cidara Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cidara Therapeutics
Cidara Therapeutics was founded in 2013 and raised its 1st funding round 1 year after it was founded.
Cidara Therapeutics is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Jeffrey Stein is the CEO of Cidara Therapeutics, as recorded in our data.
Cidara Therapeutics is a funded company, having raised a total of $78.35M across 8 funding rounds to date. The company's 1st funding round was a Series A of $36.33M, raised on Jun 2014.
Cidara Therapeutics has 38 employees.
Annual revenue of Cidara Therapeutics is $1.27M as on Dec 31, 2024.
Developer of novel anti-infectives for infectious diseases (bacterial and fungal). Its first product candidate is CD101 IV, an intravenous therapy in phase 1 trials for fungal infections. Besides, it has CD101 topical in the IND-enabling stage for the treatment of acute and recurrent vulvovaginal candidiasis (VVS). It has also developed a proprietary immunotherapy technology platform, Cloudbreak to develop drugs that direct immune cells to eliminate pathogens that cause infectious diseases. Its first Cloudbreak development candidate C001 is for the treatment of invasive aspergillosis.
Cidara Therapeutics's top competitors include BeiGene, Vaxcyte and Vir Biotechnology.
Cidara Therapeutics offers Cloudbreak Platform.
Yes, Cidara Therapeutics is publicly traded on NASDAQ under the ticker symbol CDTX.
Cidara Therapeutics has 24 investors. Key investors include Merck, Fidelity Investments, NIH, RA Capital, and Frazier Healthcare Partners.
Cidara Therapeutics operates through Cidara Therapeutics, Inc..

